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Personal View: Should haemoglobin A1C be used for 
diagnosis of diabetes mellitus in Malawi?
Introduction
Glycated haemoglobin (haemoglobin A1c or HbA1c) level 
has long been utilised for assessment of  long-term glycaemic 
control in patients with diabetes mellitus.1 More recently it 
has also been included as a criterion for the diagnosis of  type 
2 diabetes mellitus.2 However, use of  HbA1c as a diagnostic 
tool for diabetes is controversial.3 This article discusses some 
of  the limitations, and explores whether HbA1c should be 
recommended for diagnosis of  diabetes mellitus in Malawi 
and similar settings.
HbA1c formation and structure 
HbA1c is modified haemoglobin, with a glucose linked to 
the N-terminal valine of  the beta chain.4 It is made in vivo by 
the non-enzymatic attachment of  glucose to haemoglobin.5 
This occurs first by formation of  a labile adduct aldimine, 
which is a Schiff  base, that then rearranges to form a more 
stable ketoamine (Figure 1).6 The rate at which this reaction 
occurs is related to the prevailing glucose concentration, and 
it is expressed as a percentage of  the total haemoglobin.7
Figure 1: Formation of glycated haemoglobin (HbA1c)
HbA1c and diabetes diagnosis
The diagnosis of  diabetes has traditionally been based upon 
the detection of  elevated plasma glucose levels, either after 
fasting, two hours after an oral glucose (75 g) tolerance test 
(OGTT), or, in symptomatic individuals, after a random 
blood glucose check.13 Recently, the American Diabetes 
Association and the WHO have recommended using HbA1c 
(greater than or equal to 6.5%) to diagnose diabetes mellitus.14 
This was based, in part, on the ability for HbA1c to predict 
clinical outcomes. It has been established that HbA1c has a 
similar relationship with prevalent diabetic retinopathy as that 
of  both fasting and two-hour plasma glucose levels, and that 
lowering HbAlc can reduce microvascular complications.15,16
Although HbA1c testing is currently more expensive than 
blood glucose measurements (the net cost of  an HbA1c 
test is, on average, 13.6 times higher than a plasma glucose 
measurement3), it provides significant practical advantages. 
HbA1c testing can be performed at any time of  the day 
and does not require any special pre-test preparation by the 
patient (for example, overnight fasting or glucose loading).17,18
While the use of  HbA1c for long-term glycaemic control is 
well accepted, there remains significant controversy on its 
use as a diagnostic tool, and many studies show significant 
discordance between fasting glucose and HbA1c tests.19
Factors affecting HbA1c levels
There are many common factors, including genetic 
and medical conditions, that influence HbA1c and its 
measurement, even when glucose levels are constant.20,21 
Several studies have shown that in recent-onset, drug-naïve 
type 2 diabetes (controlling for age, sex and BMI), there is 
ethnic variability of  HbA1c, despite similar fasting plasma 
glucose levels and similar or lower post-glucose load glucose 
levels.22,23 People of  African descent and South Asians appear 
to have significantly higher levels of  HbA1c (and therefore 
levels “diagnostic” of  diabetes) across the full spectrum 
of  glycaemia,21 compared to Caucasians.24-26 The optimal 
HbA1c threshold for detecting diabetes may thus vary by 
ethnic group27; while the WHO currently recommends a 
diagnostic HbA1c of  6.5%, other studies have shown that 
in some races a lower threshold of  6.3% can be used for 
detecting diabetes in high-risk populations.28
In addition to the ethnic limitations described above, a 
number of  other disorders influence HbA1c, and their 
frequencies will depend on the setting. Conditions that 
alter red cell lifespan alter the Hb1Ac concentrations, with 
conditions that shorten red cell survival, such as haemolysis, 
decreasing HbA1c, and those disease states that prolong red 
cell survival increasing HbA1c,29 owing to the change in the 
duration of  contact of  the red blood cells with glucose in 
the blood. Thus, decreased erythropoiesis caused by iron or 
vitamin deficiency may cause increased HbA1c; and increased 
erythropoiesis caused by haemolysis (for example, in malaria), 
administration of  erythropoietin, iron, vitamin B12, and 
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HbA1c in monitoring diabetes control 
The potential utility of  HbA1c in management of  diabetes 
was proposed in 1976 by Ronald Koenig and Anthony 
Cerami8; and a 1985 World Health Organization (WHO) 
report recommended its use for practical assessment of  long-
term glycaemic control in patients with diabetes mellitus.1 In 
individuals with a normal red blood cell lifespan, the level of  
HbA1c is related to the circulating plasma levels of  glucose,9 
as well as the average glycaemia of  the previous 12 to 16 
weeks, as this is the half-life of  red blood cells.6 HbA1c 
is considered the gold-standard biochemical indicator 
of  long-term glycaemic control in diabetic patients,10 as a 
good association has been demonstrated with the chronic 
microvascular complications of  diabetes, such as retinopathy, 
nephropathy and neuropathy.2,11 HbA1c of  less than 6.0% is 
considered normal, 6.0% to 7.5% is good control of  diabetes 
mellitus, 7.6% to 9.0% is considered unsatisfactory control, 
and HbA1c of  more than 9.0% is regarded as very poor 
control of  diabetes mellitus. In Blantyre, Malawi, Cohen et al., 
in a survey of  the management, control, and complications 
of  diabetes mellitus in patients attending a diabetes clinic, 
found that 74% of  patients had unsatisfactory levels of  
HbA1c (greater than 7.5%), and this was accompanied by a 
high frequency of  microvascular complications.12
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reticulocytosis, will lead to its decrease. Decreased lifespan 
of  red blood cells resulting from haemoglobinopathies, 
splenomegaly (also common in malaria) rheumatoid arthritis, 
or drugs (for example, antimicrobials such as ribavirin and 
dapsone) can also decrease HbA1c.
Table 1: Some factors that influence glycated haemoglobin (HbA1c) 
and its measurement
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Factor influencing HbA1c Increased HbA1c Decreased HbA1c
Erythropoiesis Iron deficiency, vitamin B12 
deficiency, decreased 
erythropoiesis
Administration of 
erythropoietin, iron or vitamin 
B12, chronic liver disease 
Erythrocyte destruction Increased erythrocyte lifespan, 
splenectomy
Decreased erythrocyte lifespan, 
haemoglobinopathies, malaria, 
splenomegaly, rheumatoid 
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dapsone)
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pH
Assays Hyperbilirubinaemia, 
carbamylated haemoglobin, 
alcoholism, large doses of aspirin
Hypertriglyceridaemia
Modified from Gallagher et al.17
The relationship between HbA1c and HIV infection is also 
complex. Slama et al. found that at a fasting glucose of  125 
mg/dL, median HbA1c values were 0.21% lower in HIV-
infected men than in HIV-uninfected men, and that the 
magnitude of  this difference increased at higher glucose 
values.30
They also found that HbA1C discordance was associated 
with lower CD4 cell counts; high mean corpuscular volume 
(MCV); high mean corpuscular haemoglobin (MCH); and a 
regimen containing a protease inhibitor, a non-nucleoside 
reverse transcriptase inhibitor, and zidovudine.30 The 
use of  HbA1c could therefore lead to underdiagnosis or 
undertreatment of  established diabetes mellitus, particularly 
in HIV-positive people on antiretroviral therapy (ART), or 
those with advanced disease.30 This is significant since HIV 
and AIDS may have an impact on glucose metabolism, and 
there are an increasing number of  people in Malawi who are 
dually affected by HIV and diabetes.31
Finally, HbA1c testing (whether laboratory analysis or point-
of-care) requires a rigorous programme to standardise the 
assays,32 which may not be possible in many developing 
countries. Lack of  standardisation would lead to a high 
degree of  uncertainty with the results generated in these 
settings.3
Conclusions
HbA1c is a useful addition to the tools available to diagnose 
diabetes, and it has clear advantages. However, challenges 
including cost, assay standardization and multiple potential 
confounding conditions must be considered. Individual 
countries will therefore need to decide whether HbA1c 
as a diagnostic tool is appropriate in relation to prevailing 
circumstances. Malawi is resource-poor and has a high 
prevalence of  conditions that can influence the performance 
of  HbA1c (such as HIV, anaemia of  various aetiologies, 
and disorders associated with increased red cell turnover, 
including malaria). It would therefore be premature to 
advocate the use of  HbA1c to diagnose diabetes mellitus in 
Malawi. More research will be required to fully understand 
the utility of  HbA1c and its limitations in the diagnosis of  
diabetes in Malawi and sub-Saharan Africa in general.
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